Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04367675 · ClinicalTrials.gov registry record · Phase 1
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
A Phase 1 study of BRCA1/2 Mutation, sponsored by Abramson Cancer Center at Penn Medicine.
- Active
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 1
- Study location
NCT04367675 is a Phase 1 study of BRCA1/2 Mutation that is active but no longer recruiting, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 44 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04367675, a Phase 1 study of BRCA1/2 Mutation, is active but no longer recruiting, sponsored by Abramson Cancer Center at Penn Medicine.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 1
- Study location
Study Summary
The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vaccine activates your immune system.
Conditions Studied
Interventions
- DRUG INO-5401
- DRUG INO-9012
- DEVICE Cellectra 2000
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04367675
The ClinicalTrials.gov registry entry for NCT04367675 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with BRCA1/2 Mutation appearing as the primary indexed condition, and to 3 interventions - of which INO-5401 is the first listed.
NCT04367675 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04367675 about?
NCT04367675 is a clinical study titled "INO 5401 Vaccination in BRCA1/2 Mutation Carriers". The research study is being conducted to test an experimental vaccine to potentially prevent cancer for people with BRCA1 or BRCA2 mutations. This study will test if the vaccine is safe (without significant side effects) and test a new way of administering vaccines. It will also test whether the vac...
What is the current status of trial NCT04367675?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2021-04-20. Estimated completion is 2027-03.
What conditions does trial NCT04367675 study?
This clinical trial studies the following conditions: BRCA1/2 Mutation.
What interventions are being tested in trial NCT04367675?
The interventions under investigation include: INO-5401 (DRUG), INO-9012 (DRUG), Cellectra 2000 (DEVICE).
Who is sponsoring clinical trial NCT04367675?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04367675 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.